Site-targeted proximal complement C3 inhibition, but not C5 blockade, attenuates neurodegeneration in a mouse model of amyotrophic lateral sclerosis: Implications for failed clinical trials
model of ALS. Site-targeted C3 inhibition may address the mechanistic limitation underlying recent clinical trial failures and represents a translationally justified therapeutic strategy.
Authors
- S Tomlinson
- Nityananda Chowdhury (ORCID: https://orcid.org/0000-0002-8417-909X)
- Davis Borucki (ORCID: https://orcid.org/0000-0001-8669-6720)
- Khalil Mallah (ORCID: https://orcid.org/0000-0001-7622-8106)
- Moumita Majumder
Institutions
- Medical University of South Carolina (US)
- Ralph H. Johnson VA Medical Center (US)
Publication Details
- Journal
- Neurotherapeutics
- Published
- 2026-07-23
- DOI
- https://doi.org/10.1016/j.neurot.2026.e00969
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs